Oncolytics Biotech says FDA grants Fast Track status for pelareorep combo in second-line anal cancer

• Oncolytics Biotech received FDA Fast Track designation for pelareorep with a checkpoint inhibitor in second-line or later anal cancer.
• The designation follows results already presented from the GOBLET study, which showed signs of improved outcomes versus historical experience in this setting.
• Fast Track status supports a potential registrational pathway, including more frequent FDA engagement and a possible rolling BLA review.
• The company framed the opportunity as an estimated nearly USD 1 billion U.S. market with no FDA-approved options post first-line standard of care.
• This is pelareorep’s third FDA Fast Track designation in gastrointestinal cancers, adding regulatory momentum across its pipeline.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncolytics Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001129928-26-000045), on July 20, 2026, and is solely responsible for the information contained therein.